The oligonucleotide synthesis services at Aurigene is supported by a state-of-the-art lab facility and skilled scientists with expertise in various types of oligos. We have an in-house custom synthesis of phosphoramidites and the ability to perform complex conjugation using click chemistry, amide coupling and thiol mediated C-S & S-S bond.
Our dedicated lab space of 1000 sq.ft is equipped with humidity control. Aurigene’s oligonucleotide platform is supported by trained team that helps optimize the designed oligonucleotide along with primary assay iterations. We have the ability to synthesize 10-40-mer oligonucleotide up to 1-gram scale. We perform all standard modifications, with or without backbone modification, for which phosphoramidites are made in-house and also available commercially. Oligo equipments at Aurigene: K and A H-16 automated DNA/RNA synthesizer AKTA pure 25M FPLC purification system Sartoflow smart TFF system for concentration and desalting Martin Christ LSC plus lyophilizer with lyocube, benchtop tray lyophilizer Agilent LC-MS for oligonucleotide analysis Implen N60 nano spectrophotometer
Complex conjugation using click chemistry, amide coupling and thiol mediated C-S & S-S bond
Ion exchange and reverse phase HPLC
Expertise in nucleoside, sugar modifications, base modifications
State-of-the-art drug discovery facility using oligonucleotide modality
Synthesis between 10-40-mer oligonucleotide
In-house custom phosphoramidite synthesis
JULY 02, 2021
Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...Read More
The global Highly Potent Active Pharmaceutical Ingredients (HPAPI) market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%....Read More
Aurigene Pharmaceutical Services has a legacy of +20 years in developing and manufacturing compounds under cGMP. Our manufacturing plants are spread across 3 continents with facilities in India, UK, and Mexico. ...Read More
Challenges: Several repeated in house validation studies were performed to optimize the suitable perfusate (liquid medium intended to pass through the heart), perfusate volume and perfusion rate to ensure complete perfusion of animal subjects (parameters weren’t adjustable) Challenges were encountered in adjusting the perfusion volume and rate vis-à-vis ensuri...Read More
Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
Oligonucleotides can be synthesized using solid-phase (Peptides) and one pot liquid phase (enzymatic) method in the lab for milligram to multi-kilogram scale. Steps involved in solid-phase Oligo synthesis are detritylation, coupling, oxidation and capping. One-pot liquid phase oligo synthesis requires polymerase enzyme, template oligonucleotide and nucleotide triphosphate as starting materials.
Accuracy of chemical synthesis of Oligonucleotides is maintained by maintaining the order of starting materials used during the synthesis process.
Oligonucleotide drugs help modulate the effect of a disease-causing gene by targeted degradation/activation of gene expression or gene editing. This activity may cause the disease to be controlled or cured.
Oligos are stable for 6 weeks in buffer when stored at 37°C and for long-term stability is to be stored between -20°C to -80°C. During storage, oligos should not be exposed to direct sunlight or UV rays.
We can Synthesis 10-40-mer oligonucleotide up to 1 gram scale.
We can perform all standard modifications, with or without backbone modification, for which Phosphoramidites are commercially available. We also have the capabilities of making any customized Phosphoramidite in-house.
For a period of 6 weeks, Oligos can be stored in T10E1 buffer at 37°C and for the long term, Oligonucleotides can be dried down and stored with or without TE buffer at -20°C.
Typical Oligonucleotide synthesis does not produce phosphate on the 5’ or 3’ end. On request, oligonucleotides can be synthesized with phosphate on the 5’ or 3’ end.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.